Analysis of the effect of IGF1 (CA)n repeats on the growth response to rhGH therapy in patients with severe growth hormone deficiency
Everlayny Fiorot Costalonga, Sonir Roberto R Antonini, Gil Guerra-Junior, et al.
The Relationship Between IGF-1 Response and 1st year Height Velocity on two different doses of GH in Idiopathic GH Deficiency (IGHD) : A randomized, Prospective Multicentre Clinical Study
Ruveyde Bundak,İlknur Arslanoğlu, Merih Berberoğlu, et al.
Analyses of treatment variables for patients with childhood craniopharyngioma – results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up
Hermann L. Müller, Ursel Gebhardt, Sabine Schröder, et al.
Prediction model for individualized GH dosing
Kerstin Albertsson-Wikland, Berit Kriström, Jovanna Dahlgren, Aimon Niklasson, Andreas FM Nierop
Evaluation of the Prediction model used in a randomized individualized GH dose study in short GHD and ISS children, with addition of KIGS SGA dose module
Kerstin Albertsson-Wikland, Berit Kriström, Andreas FM Nierop
ISS – Evaluating Growth Response from Clinical Trials in the KIGS database
Kerstin Albertsson-Wikland, Berit Kriström, Anders Lindberg
Method To Estimate Mean Serum IGF-1 Concentration during rhIGF-1 Treatment Using a Single Blood Sample
GM Bright, S Liao, and JW Frane
Growth Response to Individualized vs. Fixed Dose Growth Hormone (GH) Treatment in Short Children Born Small for Gestational Age (SGA): Two-Year Results of the OPTIMA Trial
H Jung, C Land, WF Blum, C Nicolay, and E Schonau
The Growth Hormone-IGF-1 Axis after Bone Marrow Transplantation (BMT) with Total Body Irradiation (TBI) in Childhood: Qualitative and Quantitative Abnormalities and Impact of Adiposity
NL Davis, R Elson, CE Stewart, A Moss, W Woltersdorf, JM Cornish, MCG Stevens, and EC Crowne
Evidence for Central Regulation by Estrogen of GH Secretion in Women: A Study of the Effects of Estrogen Receptor Antagonism
V Birzniece, A Sata, SK Sutton, and KKY Ho
Hypothyroidism in Pediatric Patients Treated with Recombinant Human Growth Hormone
KN Wong, LL Levitsky, and M Misra
Serum IGF-1 Increment after a Month of Growth Hormone Treatment is Effective for Prediction of Growth Response in Idiopathic Short Stature
HW Chae, EB Lee, HS Kim, and DH Kim
Reduced Injection Dose Force Dynamics of Next Generation Norditropin NordiFlex® Compared to Current Norditropin NordiFlex® Pen Device
N-AB Hansen, M Vang-Petersen, L Hourman Ditlefsen, and A-M Kappelgaard
The Clinical Features and Therapeutic Outcomes in 110 Patients with Acromegaly at a Single Institute
I Fukuda, N Hizuka, M Kurimoto, J Morita, S Tanaka, Y Yamakado, and K Takano
Impact of Metabolic Factors on IGF-1 Levels in Treated Acromegalic Patients with Divergent GH/IGF-1 Level
M Matta, V Bongard, S Grunenwald, J-C Maiza, A Bennet, and P Caron
Four Year Efficacy and Safety Data of Treatment with Omnitrope® 5 mg/ml Lyophilized Formulation in Children with Growth Failure Due to Growth Hormone Deficiency
F Peter, T Romer, B Koehler, E Solyom, M Walczak, A Muzsnai, A Rudzka-Kocjan, E Kaluza-Guzikowska, E Petriczko, and PH Saenger
Postoperative Glycemia Is Associated with Increased Risk of Diabetes Recurrence after Pancreas-Kidney Transplantation
KB Hawkins, CM Shay, and FGS Toledo
Genetic Polymorphisms Associated with Changes in Serum IGF-I in Prepubertal Children with Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) after One Month of Growth Hormone (GH) Therapy: The PREDICT Study Introducing Pharmacogenomics into Clini
PE Clayton, P Chatelain, V Peterkova, A Belgorosky, D Veimo, A Ferrandez, M Tuefferd, J Dauvillier, L Tato, and PREDICT Investigators
Exenatide Treatment Added to a Lifestyle Modification Program was Associated with Body Weight Reduction in Obese Patients
M Trautmann, J Northrup, L Glass, D Cao, and J Holcombe
Outcome of Thiazolidinedione Withdrawal in Veteran Patients with Type 2 Diabetes
JC Leary, JL Meier, SS Lippman, RH Noth, and A Swislocki
Psychosocial Health and Levels of Employment in 851 GH Deficient Swedish Patients on Complete Hormone Replacement Including GH
Eva-Marie Erfurth, MD
High-Dose Octreotide LAR Is Effective and Safe in Patients with Acromegaly Inadequately Controlled by Conventional Somatostatin Analog Therapy: A Randomized, Controlled Trial
Gherardo Mazziotti, MD
Impact of Therapeutic Interventions on the Long-Term Outcome of Persistent Differentiated Thyroid Cancer
Ali S. Alzahrani, MD
Hereditary Vitamin D Resistant Rickets: Identification of a Novel Splice-Site Mutation in the Vitamin D Receptor Gene and Successful Treatment with Oral Calcium Therapy
Nina Ma, MD
Clinical and Biochemical Features in 6 Adult Patients with Primary Adrenal Ganglioneuromas
Geneviève Rondeau, MD
Normal Final Height after Late Growth Hormone Treatment of Patients with Growth Hormone Deficiency
Ivo Arnhold, MD
Plasma CNP Forms in Prepubertal Children with Acquired Thyroid Disease: Correlation with Thyroid Status and Bone-Specific Alkaline Phosphatase
Christine Southern Reh, MD
Effects of Doubled GH Dose on Growth Parameters in Early Pubertal GHD Patients
Giuseppe Saggese, MD
Six Months Efficacy and Safety of a Novel Once-a-Week Sustained Release RhGH (LB03002) in Adults with GHD; A Phase III, Double-Blind Placebo-Controlled Study
Beverly M.K. Biller, MD
Craniofacial and Extremity Growth Evaluation in Patients with Turner Syndrome during Growth Hormone Therapy
Maria Estela Justamante de Faria, MD
Growth Hormone Administration Reduces Visceral Adiposity and HsCRP in Patients with Growth Hormone Deficiency Following Cure of Acromegaly: A Randomized, Placebo-Controlled Study
Karen K. Miller, MD